Participants should be able to describe at least 1 potential role for Janus kinase 2 (JAK2) inhibitors in the treatment of myeloproliferative neoplasms.

Participants should be able to describe at least 1 potential role for Janus kinase 2 (JAK2) inhibitors in the treatment of myeloproliferative neoplasms.

Use pathologic correlation to better understand the imaging appearance of focal liver lesions

Explain the key imaging findings to characterize common and rare liver lesions

Participants should be able to describe the role of novel therapies, including bortezomib and lenalidomide, in the treatment of patients with newly diagnosed multiple myeloma.

• Describe the pathologic features of MCL.
• List at least 2 initial therapy options for managing MCL.
• Discuss the role of autologous and allogeneic stem cell transplantation in managing MCL.

1) Incorporate recent innovations in the surgical management of non-small cell lung cancer (NSCLC), including the use of minimally invasive techniques and multimodal treatment strategies, into their current management practices by applying expert faculty recommendations.

2) Enhance their competence and skills in the selection of appropriate therapeutic alternatives for high risk NSCLC patients who have limited pulmonary reserves by making recommended practice changes. Make therapeutic choices for early stage, locally advanced and advanced NSCLC that align with recent clinical evidence and expert recommendations as outlined in the educational activity.

Assess the prognostic and therapeutic significance of emerging evidence that the triple-negative breast cancer subtype has preferential sites of metastatic relapse, particularly the brain and viscera.

Participants in the activity should be able to list at least 2 important factors that indicate the potential presence of a familial syndrome, and describe at least 2 differences in managing familial vs sporadic gastrointestinal cancers.

Summarize the options for treatment and prevention of recurrence in advanced pancreatic cancer and assess how well these options have been integrated into their current practices.

List emerging treatment options for hepatocellular cancer and describe specific steps for incorporating these new options in their practices.

Discuss emerging clinical data on the role of intensive glycemic control in reducing the cardiovascular risk of patients with type 2 diabetes mellitus in the short- and long-term.